Tag Archives: Biocept

Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets. Biocept, Inc., provider of liquid biopsy tests designed to provide...

Biocept, Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical Center ...

Company’s intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology Biocept, Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer ...

The Addario Lung Cancer Medical Institute (ALCMI), a non-profit, patient-centric, international research organization, and Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announce a clinical collaboration ...

Biocept, Inc. announces that it has been awarded Japanese Patent No. 6081434 entitled,. The issued patent covers the use of antibodies for the capture of any target of interest from any sample type on a device surface. This includes CTCs, ...

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces a collaboration with Catalyst Pharmaceuticals for the provision of Biocept’s Target Selector™ platform to ...

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests ...

from Prostate Cancer News Today – by Inês Martins – Biocept and Dr. Shilpa Gupta, an expert in cancers of the genitourinary tract, are working together to develop liquid, or blood-based, biopsies for patients with bladder and prostate cancer that may ...

Biocept Inc, a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces a preferred provider agreement with Teneovita Medical, a division of Teneovita Medical Innovations, Inc. ...

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces the initiation of a collaborative study with MedStar Georgetown University Hospital to evaluate resistance biomarkers in patients diagnosed ...